Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE2

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University People's hospital, Beijing, China
Contact: Study coordinator (Jianzhong Zhang) · rmzjz@126.com · 15545433012

Study leads

Jianzhong Zhang
Principal Investigator
Peking University People's Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Atopic Dermatitis (AD)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

The Bronx, United States

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

St. Petersburg, United States

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Healthy Participants · Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE1

Anaheim, United States · Miami, United States